Trials / Terminated
TerminatedNCT02239354
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus
A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- ViaCyte · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years. It will also test if VC-01 is an effective treatment for subjects with Type 1 Diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | VC-01™ Combination Product | Biologic and Device |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2014-09-12
- Last updated
- 2022-03-24
- Results posted
- 2022-03-24
Locations
2 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02239354. Inclusion in this directory is not an endorsement.